Genespire is a developer of transformative gene therapies for people affected by genetic diseases. The companys lead product is GENE 101 for X-linked HIGM syndrome, with other candidates including GENE 102, 201, and 202 for inherited metabolic diseases. The company leverages advanced gene therapy platforms to develop treatments addressing the underlying genetic causes of rare diseases, aiming to provide durable therapeutic benefits for patients with limited treatment options. Founded in 2019 and headquartered in Milano, Italy, Genespire has raised approximately 69.3 million at the Series B stage with 17 employees and investors including Sofinnova Partners, XGEN Venture, CDP Venture Capital, and Indaco Venture Partners.
← All startups
Genespire
Series BGenespire is a developer of transformative gene therapies for people affected by genetic diseases. The companys lead product is GENE 101 for X-linked HIGM syndrome, with other candidates including GENE 102, 201, and 202 for inherited metabolic diseases. The company leverages advanced gene therapy platforms to develop treatments addressing the underlying genetic causes of rare diseases, aiming to provide durable…
About
Business model
Life Sciences Tech > Research & Development > Drug Discovery > Genomics > Drug Development,
Metabolic Diseases > Drugs > Diversified,
Immunology > Drugs > Hyper IgM Syndrome,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Institutional investors
Sofinnova PartnersXGEN VentureCDP Venture CapitalIndaco Venture Partners
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Backed by funds in our directory
Sofinnova Partners
Investor profile on CrackTheDeckCDP Venture Capital
Investor profile on CrackTheDeck🗂️ Full list of active funds — filter by stage, check size, and geography.